Solventum Corporation · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · United States
Solventum Corporation, a healthcare company, develops, manufactures, and commercializes a portfolio of solutions to address critical customer and patient needs in the United States and internationally. It operates through three segments: Medsurg, Dental Solutions, and Health Information Systems. The Medsurg segment offers solutions, such as negative pressure wound therapy, advanced wound dressings, advanced skin care, synthetic tissue matrices, I.V. site management, sterilization assurance, temperature management, surgical supplies, medical tapes and wraps, stethoscopes, medical electrodes, and medical technologies for original equipment manufacturers. The Dental Solutions segment provides dental and orthodontic products, including brackets, aligners, restorative cements, and bonding agents to span the life of the tooth, and products for preventative dental care, direct and indirect restoration, and orthodontic needs. The Health Information Systems segment offers healthcare systems with software solutions comprising computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. The company sells its products and services through direct-to-consumer, distribution, key account management, inside sales, and e-commerce. Solventum Corporation was incorporated in 2023 and is headquartered in Eagan, Minnesota.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-09$86.14 RISE2026-04-07$62.49 PEAK2026-05-22$76.83 133d | -27.5% 88d | Missed | Missed | — | — | +22.9% 45d | Missed |
DROP2025-07-03$78.50 RISE2025-11-06$66.28 PEAK2026-01-09$86.14 190d | -15.6% 126d | Missed | Missed | — | — | +30.0% 64d | Missed |
DROP2025-02-26$84.04 RISE2025-04-08$63.01 PEAK2025-07-03$78.50 127d | -25.0% 41d | Missed | Missed | — | — | +24.6% 86d | Missed |
DROP2024-03-26$80.00 RISE2024-07-09$48.02 PEAK2024-09-19$72.34 177d | -40.0% 105d | 2024-08-13 $58.22 | 2024-09-19 $72.34 | 73Deep Value | 62Deep Value | +50.6% 72d | +24.3% Held 37d |
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
While Solventum has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
While Solventum has considerably underperformed the broader market over the past 52 weeks, Wall Street analysts maintain a moderately optimistic outlook about the stock’s prospects.
Spin-offs and mergers can lead to major movement for share prices, but accessing these scenarios can be challenging for investors; these ETFs can help.
Spin-offs and mergers can lead to major movement for share prices, but accessing these scenarios can be challenging for investors; these ETFs can help.
SOLV vs. HQY: Which Stock Is the Better Value Option?
SOLV vs. HQY: Which Stock Is the Better Value Option?
Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating
Solventum (SOLV) shows a convergence of catalysts that should drive a meaningful valuation re-rating
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
Cisco upgraded, Doximity downgraded: Wall Street's top analyst calls
Wedbush analyst Michael Piccolo initiates coverage on Solventum (NYSE:SOLV) with a Outperform rating and announces Price Target of $94.
Solventum’s first quarter results reflected the impact of ongoing transformation initiatives, new product launches, and portfolio adjustments. Management pointed to strong commercial execution and positive volume and mix as contributing factors. CEO Bryan Hanson credited “the team’s ability to drive outcomes while navigating ongoing separation efforts, ERP implementations, and acquisitions and divestitures” as key to the quarter’s performance. Hanson also highlighted that advanced wound care, de
Solventum’s first quarter results reflected the impact of ongoing transformation initiatives, new product launches, and portfolio adjustments. Management pointed to strong commercial execution and positive volume and mix as contributing factors. CEO Bryan Hanson credited “the team’s ability to drive outcomes while navigating ongoing separation efforts, ERP implementations, and acquisitions and divestitures” as key to the quarter’s performance. Hanson also highlighted that advanced wound care, de
GE Vernova is the IBD Stock Of The Day, showing bullish action near highs after a big beat-and-raise earnings report, powered by global megatrends in technology and energy. In just the first quarter of 2026, Vernova's electrification segment booked $2.4 billion in equipment orders to support data centers — more than all of last year, the company said in April. GE Vernova's three business segments — electrification, power and wind — serve the rising markets for artificial intelligence, data centers, grid modernization and lower-carbon energy.
Tight weekly action near highs and a possible new buy point have made GE Vernova stock our pick. Amazing earnings help too.
Solventum Corporation (SOLV) Bank of America Global Healthcare Conference 2026 May 13, 2026 1:00 PM EDTCompany ParticipantsGarri GarrisonAmy Wakeham -...
Presenter SpeechTravis Steed Travis Steed, Bank of America medical device analyst. Welcoming Solventum Corporation next up in Vegas. We have Garri Garrison, President of Health Information Systems;...
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| SOLV | +12.49% | +2.67% | -5.41% | +2.54% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | +9.52% | +8.39% | -1.97% | -10.14% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 6.41M | $418.41M | 0.01% | Added+1.0% | 2026-03-31 |
| FidelityFMR | fundamental | 1.87M | $122.11M | 0.01% | Trimmed-3.9% | 2026-03-31 |
| DEShaw | quant | 145.9K | $9.53M | 0.01% | Trimmed-26.3% | 2026-03-31 |
| Wellington | fundamental | 34.3K | $2.24M | 0.00% | Added+3.3% | 2026-03-31 |
| Bridgewater | macro | 3.4K | $220.58K | 0.00% | Trimmed-74.6% | 2026-03-31 |
| TRowePrice | fundamental | 215.9K | $14.10K | 0.00% | Unchanged | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-18 | Wilson Darryl L. | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | Wendell Amy McBride | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | WEILAND JOHN H | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | Mily Elizabeth | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | MAY KAREN J | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | Harris Bernard A Jr | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | EISENBERG GLENN A | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | Edwards Shirley Ann | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | DeVore Susan D. | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-18 | COX CARRIE SMITH | Director | A Grant / award(deriv) | 4,848 | — | +$0 |
| 2026-05-18 | ALBAN CARLOS | Director | A Grant / award(deriv) | 3,300 | — | +$0 |
| 2026-05-15 | Landucci Amy | Chief Information Officer | M Option exercise(deriv) | 4,422 | — | +$0 |
| 2026-05-15 | Landucci Amy | Chief Information Officer | F Tax withholding | 2,017 | $74.41 | −$150.1K |
| 2026-05-15 | Landucci Amy | Chief Information Officer | M Option exercise | 4,422 | — | +$0 |
| 2026-05-15 | Hanson Bryan C | Chief Executive Officer | M Option exercise(deriv) | 34,315 | — | +$0 |
| 2026-05-15 | Hanson Bryan C | Chief Executive Officer | F Tax withholding | 13,503 | $74.41 | −$1.00M |
| 2026-05-15 | Hanson Bryan C | Chief Executive Officer | M Option exercise | 34,315 | — | +$0 |
| 2026-05-15 | Kirberger Marcela A. | Chief Legal Affairs Officer | M Option exercise(deriv) | 4,488 | — | +$0 |
| 2026-05-15 | Kirberger Marcela A. | Chief Legal Affairs Officer | F Tax withholding | 1,952 | $74.41 | −$145.2K |
| 2026-05-15 | Kirberger Marcela A. | Chief Legal Affairs Officer | M Option exercise | 4,488 | — | +$0 |
| 2026-05-15 | Wilcox Mary T | Chief Accounting Officer | M Option exercise(deriv) | 2,376 | — | +$0 |
| 2026-05-15 | Wilcox Mary T | Chief Accounting Officer | F Tax withholding | 728 | $74.41 | −$54.2K |
| 2026-05-15 | Wilcox Mary T | Chief Accounting Officer | M Option exercise | 2,376 | — | +$0 |
| 2026-05-15 | Harrington Paul S | Chief Supply Chain Officer | M Option exercise(deriv) | 3,960 | — | +$0 |
| 2026-05-15 | Harrington Paul S | Chief Supply Chain Officer | F Tax withholding | 1,678 | $74.41 | −$124.9K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 1.89 | — | — |
| 2026-05-05 | 1.35 | 1.48 | +9.33% |
| 2026-02-26 | 0.69 | 0.36 | -47.83% |
| 2025-11-06 | 1.43 | 1.50 | +4.73% |
| 2025-08-07 | 1.45 | 1.69 | +16.25% |
| 2025-05-08 | 1.22 | 1.34 | +9.71% |
| 2025-02-27 | 0.67 | 0.17 | -74.75% |
| 2024-11-07 | 1.39 | 1.64 | +17.67% |
| 2024-08-08 | 1.51 | 1.56 | +3.65% |
| 2024-05-09 | 1.75 | 2.08 | +19.20% |